Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MicroVision Inc MVIS

MicroVision, Inc. is a developer and supplier of lidar hardware and software solutions focused on the automotive lidar and advanced driver-assistance systems (ADAS) markets. It is engaged in micro-electromechanical systems (MEMS)-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its technology to address existing and emerging markets. Its patented laser beam scanning technology combines a MEMS scanning mirror, laser diode light sources, electronics, and optics that are controlled using its system control algorithms, along with edge computing and machine learning in some systems. It has developed micro-display concepts and designs for use in head-mounted augmented reality (AR) headsets and developed a 1440i MEMS module supporting AR headsets. It also developed an interactive display solution targeted at the smart speaker’s market and a small consumer lidar sensor for use indoors with smart home systems.


NDAQ:MVIS - Post by User

Post by Roseeneon Jun 03, 2022 4:52am
91 Views
Post# 34728725

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance




FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>